Skip to main content

Search form

Search

Medicines for Malaria Venture

Developing antimalarials to save lives

Research & Development
Access
Partnering
Our impact
About us
Malaria & medicines
Newsroom
MMV Open

Home
Newsroom
News & Press Releases

News & Press Releases

Filter

Category

Topic

Search Terms

456 found

This World Malaria Day MMV joins Swiss Malaria Group in calling for increased commitment to combatting malaria

MMV welcomes Alan Court as new Board Chair

Dr Pedro Alonso retires from position as Director of WHO’s Global Malaria Programme

Boards for all? A review of power, policy and people on the boards of organisations active in global health. Read now at bit.ly/GH50502022. #Boardsforall. A picture of a double-pan balance with silhouettes of men in suits in one pan and a lone woman in the other.

Global Health 50/50 launches report Boards for all?

Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration

Access & product management

Professor Michael Ferguson receives British Society for Parasitology Honorary Membership

Ongoing challenges and renewed commitment: MMV’s progress in 2021

MMV supports open letter urging decision makers to scale-up access to preventive malaria treatment in pregnancy

Malaria kills more children than previously estimated according to World Malaria Report

MMV deeply saddened by the loss of Dr Martin de Smet

Access & product management

MMV launches innovative drug research tool

Dr Elizabeth Winzeler elected to the National Academy of Medicine

First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration

Access & product management

First-ever malaria vaccine to get WHO recommendation for roll-out

Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria

MMV mourns the loss of Dr Tachi Yamada

New partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

Access & product management

Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa

MMV devises a predictive tool to assess resistance to antimalarial compounds and guide their development

MMV and DNDi urge WHO member states to invest in medicines for women and children

MMV and partners recognize malaria innovations and urge WHO member states to scale up investments

MMV recognizes partner Novartis’ milestone of 1 billion courses of antimalarial delivered

MMV deeply saddened by the loss of Ambassador Dr Konji Sebati

SMC scale-up significantly reduces child mortality in the Sahel

Access & product management

MMV’s partner S Kant receives WHO prequalification for its protective medicine for children

Access & product management

This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria

MMV mourns the loss of Professor Sir Colin Dollery

New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010

Republic of Korea grants USD 10 million to MMV-led consortium to protect children from malaria in the Sahel

Access & product management

GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration

Access & product management

Looking Back at An Extraordinary Year

MMV awards Project of the Year 2020 to Professor David Fidock and team for critical contribution to malaria drug resistance profiling

MMV’s Adam Aspinall appointed as Chair of the new Fight the Fakes Alliance

Access & product management

MMV supports the launch of the new Fight the Fakes Alliance

Access & product management

World Malaria Report highlights two decades of progress while calling for increased commitment as gains plateau

Largest clinical trial in Africa to treat COVID-19 cases before they become severe

GSK and MMV present positive data on treatment of Plasmodium vivax malaria

Endemic countries in South America meet to discuss new tools for malaria elimination

Global call to boost access to lifesaving malaria treatment for pregnant women in Africa

Despite early indicators of artemisinin resistance in Rwanda, ACTs continue to cure malaria

MMV awards Project of the Year 2019 to Novartis for the discovery of INE963

MMV launches Malaria Libre, a new open source drug discovery programme

ESAC member Sir Simon Campbell inducted into the RSC-BMCS Hall of Fame

MMV deeply saddened by the loss of Dr Ricardo Thompson

MMV’s Dr James Duffy appointed to RSC Lectureship

MMV launches the COVID Box to stimulate new drug research

R&D, Open source

MMV submits statement to 73rd World Health Assembly

This World Malaria Day MMV supports Swiss Malaria Group's call for urgent action

Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria

Access & product management

In support of the COVID-19 response

MMV and LSTM collaborate to fill data gap on use of antimalarials during pregnancy

International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa

Malaria continues to strike pregnant women and children hardest and new tools are critical, according to WHO’s latest report

Laboratory image

Research for new drugs against neglected diseases and malaria in Brazil to receive funding boost totaling BRL 43.5 million

MMV presents Lifetime Achievement Awards to three longstanding collaborators

Country leaders pledge to boost malaria innovation and access to new and existing antimalarials

Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of P. vivax malaria

Access & product management

MMV and PATH strengthen ties with APLMA in the fight against relapsing malaria

WHO issues information note about Pyramax® (artesunate-pyronaridine) for uncomplicated malaria

MMV contributes to the fight against schistosomiasis

Pages

1
2
3
4
5
6
7
8
next ›
last »

Follow us

Facebook
LinkedIn
Twitter
YouTube

Subscribe

Sign up to our monthly newsletter

Previous newsletters

Contact us

Tel: +41 22 555 03 00
- Message us
- Office directions

© MMV 2022

Website by Manta Ray Media

Glossary
Disclaimer
Privacy
Sitemap